Navigation Links
Elbit Imaging Ltd. Announces Standard & Poor's Maalot Changes Rating of Company and its Subsidiary Notes
Date:9/6/2011

TEL AVIV, Israel, September 6, 2011 /PRNewswire/ --

Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, that Standard & Poor's Maalot, has decided to change the rating of all of the Company's Series A through Series G Notes and Series 1 Notes and of its subsidiary, Plaza Centers N.V.'s Series A and Series B Notes, which are traded on the Tel Aviv Stock Exchange, from an "ilA/Watch Negative" credit rating, to an "ilBBB+/Negative" credit rating. Both the Company and Plaza Centers N.V. were removed from Watch-list.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management, primarily in major European cities; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India and in Eastern Europe; (vi) Fashion Apparel - Distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activities - (a) venture capital investments and (b) investments in hospitals and farm and dairy plants in India. We have presently decided to suspend our investment activities in hospitals and farm and dairy plants in India until we are satisfied that the economy has recovered sufficiently to resume such activities.


Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2010, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.


'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
2. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
3. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
4. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
5. Elbit Imaging Ltd. Announces First Quarter Results for 2010
6. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
7. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
8. Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes
9. Elbit Imaging Ltd. Announces Second Quarter Results for 2011
10. Elbit Imaging Announces Availability of Investor Relations Presentation - Analysis Sources and Uses
11. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Adding to its expanding ... of Medicine and NEJM Journal Watch, announces the release of NEJM Knowledge+ ... a panel of pediatricians from leading medical centers. The content was then reviewed ...
(Date:3/27/2017)... Little Rock, AR (PRWEB) , ... March 27, 2017 , ... ... the CMSA National Board of Directors on June 30, 2017. CMSA’s membership has ... board. In addition to our current Military Advisory position, a new VA Advisory position ...
(Date:3/27/2017)... ... 27, 2017 , ... Osteitis pubis may be commonplace and ... it occurs when the muscles around the pelvis become inflamed. Over time, untreated ... torso, as well as accompanying tenderness and weakness. Without proper intervention, it can ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, ... second year in a row; they are the recipient of the prestigious “Best ... voted on the award at Design Connections 2017. Top A&D professionals from leading ...
Breaking Medicine News(10 mins):